DNA
Ginkgo Bioworks Holdings, Inc.
NYSE · Healthcare · Biotechnology · US
$7.88
+0.51%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.83
From 52W high−51.18%
Volume1.75M
Market cap$530.64M
P/E (TTM)—
P/S (TTM)4.7x
Div yield—
Key dataSep 18, 2026
Open
$7.83
From 52W high
−51.18%
Volume
1.75M
Market cap
$530.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
—
RSI (14)
56.6
MomentumView details →
1D Return
+0.51%
YTD Return
−7.34%
SummaryUpdated Jun 1, 2026
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is a biotechnology platform company founded in 2008 and headquartered in Boston, Massachusetts. The company went public in April 2021 through a SPAC merger. Ginkgo operates as a "platform for cell programming," essentially functioning as a biotechnology foundry that engineers microorganisms to produce various products for customers across multiple industries. The company has evolved from a pure-play cell engineering service provider to a diversified biotechnology platform offering cell programming services, biosecurity solutions, and laboratory automation tools.
Similar companies
Latest newsMore news →
Ginkgo Bioworks (DNA) shares surged 11.1% in the prior trading session on higher-than-average trading volume.2d agoGinkgo Bioworks Holdings, Inc. (DNA) shares rose 1% to close at $7.06 in the most recent trading session.4d agoGinkgo Bioworks reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period.44d ago